PLSE Share Price | Pulse Biosciences, Inc. Stock Analysis & Recommendation

Q: How big is Pulse Biosciences, Inc.?

Market Cap: As of Jun 18, Pulse Biosciences, Inc. has a market capitalization of 1,011.80 million, classifying it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Pulse Biosciences, Inc. reported net sales of 0.00 million and a net profit of -60.25 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 114.86 million and total assets of 134.06 million.

Q: What does Pulse Biosciences, Inc. do?

Overview: Pulse Biosciences, Inc. is a clinical-stage medical device company in the Pharmaceuticals & Biotechnology industry, focusing on a non-thermal electroceutical treatment technology called Nano-Pulse stimulating (NPS).Financial Snapshot: Most recent Net Profit: -17 Million (Quarterly Results - Mar 2025) Market cap: USD 1,011.80 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.00 Return on Equity: -49.26% Price to Book: 8.54Contact Details: Address: 3957 Point Eden Way, HAYWARD CA : 94545-3720 Tel: 1 510 9064600 Fax: 1 302 6555049 Website: http://www.pulsebiosciences.com/

Q: Is Pulse Biosciences, Inc. overvalued or undervalued?

As of 30 March 2023, the valuation grade for Pulse Biosciences, Inc. has moved from risky to does not qualify, indicating a significant shift in its financial standing. The company is currently overvalued, particularly given its negative performance metrics. The P/E ratio is not applicable due to the company being loss-making, while the Price to Book Value stands at 9.71, and the EV to EBITDA ratio is at -17.01, highlighting substantial financial distress.In comparison to its peers, Pulse Biosciences, Inc. shows a less favorable position; for instance, AngioDynamics, Inc. has a P/E of -21.90 and an EV to EBITDA of 373.39, while Alpha Tau Medical Ltd. has a P/E of -7.72 and an EV to EBITDA of -5.48. These ratios suggest that Pulse is not only struggling but also lacks the financial metrics to support its current valuation. Despite a strong one-year stock return of 44.23% compared to the S&P 500's 10.26%, the underlying financial ratios indicate that the stock is not justified at its current price of 15.49.

Q: Is Pulse Biosciences, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Pulse Biosciences, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The Bollinger Bands are mildly bullish on both weekly and monthly charts, and the daily moving averages also reflect a mildly bullish stance. However, the KST shows a bullish weekly trend but is mildly bearish monthly, and Dow Theory indicates a mildly bearish weekly trend against a mildly bullish monthly trend. In terms of performance, the stock has underperformed compared to the S&P 500 over the past week, month, and year, but has significantly outperformed over the last three years. Overall, the current technical stance is mildly bullish, driven by the positive signals from the moving averages and Bollinger Bands, despite some bearish indicators on the monthly timeframe.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

335.74 k

Shareholding (Dec 2025)

FII

0.67%

Held by 36 FIIs

DII

94.57%

Held by 5 DIIs

Promoter

0.00%

How big is Pulse Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Pulse Biosciences, Inc. has a market capitalization of $1.01 billion, with net sales of $0.00 million and a net profit of -$60.25 million over the last four quarters. The company reported shareholder's funds of $114.86 million and total assets of $134.06 million as of Dec 24.

View full answer

What does Pulse Biosciences, Inc. do?

22-Jun-2025

Pulse Biosciences, Inc. is a clinical-stage medical device company specializing in non-thermal electroceutical treatment technology called Nano-Pulse stimulation. As of March 2025, it has a market cap of approximately $1.01 billion and reported a net profit loss of $17 million.

View full answer

Who are in the management team of Pulse Biosciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Pulse Biosciences, Inc. includes Mr. Darrin Uecker as CEO and Independent Chairman Mr. Robert Duggan, along with several Independent Directors: Mr. Kenneth Clark, Mr. Mitchell Levinson, Mr. Manmeet Soni, and Dr. Mahkam Zanganeh.

View full answer

Is Pulse Biosciences, Inc. overvalued or undervalued?

25-Jun-2025

As of March 30, 2023, Pulse Biosciences, Inc. is overvalued at $15.49 due to significant financial distress, reflected in its negative performance metrics and unfavorable comparisons to peers, despite a strong one-year stock return of 44.23%.

View full answer

Is Pulse Biosciences, Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Pulse Biosciences, Inc. shows a mildly bullish technical trend, supported by positive moving averages and Bollinger Bands, despite mixed signals from MACD and KST indicators and underperformance relative to the S&P 500 in the short term.

View full answer

Compare Pulse Biosciences, Inc. with Similar Stocks

NeuroPace, Inc.ZimVie, Inc.Alpha Tau Medical Ltd.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1,484 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.98

Return on Equity

-90.24%

Price to Book

18.40

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Dec 2025)

Net Profit:

-17 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

53.69%

6 Months

19.33%

1 Year

38.21%

2 Years

125.51%

3 Years

641.61%

4 Years

290.46%

5 Years

-7.96%

Pulse Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

6.19%

EBIT Growth (5y)

-14.37%

EBIT to Interest (avg)

-52.89

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.00

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

10.68%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

18.40

EV to EBIT

-18.26

EV to EBITDA

-18.52

EV to Capital Employed

942.35

EV to Sales

1405.04

PEG Ratio

Dividend Yield

ROCE (Latest)

-5160.23%

ROE (Latest)

-90.24%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 19 Schemes (4.76%)

Foreign Institutions

Held by 36 Foreign Institutions (0.67%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 200.00% vs 0.00% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 10.31% vs -1.04% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.30",
          "val2": "0.10",
          "chgp": "200.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-18.00",
          "val2": "-20.10",
          "chgp": "10.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.40",
          "val2": "-19.40",
          "chgp": "10.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-69,140.20%",
          "val2": "-236,825.60%",
          "chgp": "16,768.54%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -35.82% vs -27.01% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-75.90",
          "val2": "-53.20",
          "chgp": "-42.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-1.90",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-72.80",
          "val2": "-53.60",
          "chgp": "-35.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-219,825.70%",
          "val2": "0.00%",
          "chgp": "-21,982.57%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.30

0.10

200.00%

Operating Profit (PBDIT) excl Other Income

-18.00

-20.10

10.45%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-17.40

-19.40

10.31%

Operating Profit Margin (Excl OI)

-69,140.20%

-236,825.60%

16,768.54%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 200.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 10.31% vs -1.04% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.30

0.00

Operating Profit (PBDIT) excl Other Income

-75.90

-53.20

-42.67%

Interest

0.00

Exceptional Items

0.00

-1.90

100.00%

Consolidate Net Profit

-72.80

-53.60

-35.82%

Operating Profit Margin (Excl OI)

-219,825.70%

0.00%

-21,982.57%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -35.82% vs -27.01% in Dec 2024

All Annual Results

Company CV

About Pulse Biosciences, Inc.

Pulse Biosciences, Inc.

Pharmaceuticals & Biotechnology

Pulse Biosciences, Inc. is a clinical-stage medical device company using a platform technology called Nano-Pulse stimulating (NPS). NPS is a non-thermal, precise, focal drug-free electroceutical treatment technology that initiates cell death within treated tissue. NPS provides treatment in a range of immuno-oncology, dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret's esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing PulseTx system (PulseTx), a system for the delivery of NPS treatments. The PulseTx system delivers NPS pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.

Company Coordinates

Company Details

3957 Point Eden Way , HAYWARD CA : 94545-3720

Tel: 1 510 9064600

http://www.pulsebiosciences.com/

Registrar Details